Johnson & Johnson has built the most comprehensive base of healthcare businesses in the world, generating approximately 70% of its revenues from its number one or number two global leadership positions in its respective markets. Its consumer products, pharmaceuticals, medical devices and diagnostics play a role in helping millions of people be well and stay well every day. The company remains committed to improving the health and well-being of people everywhere, profitably growing its businesses and enhancing the value it can bring to its shareholders.
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Stephen O'Neil, Hilliard Lyons
" Double-digit growth in two segments contributed to higher Q1 sales for Johnson & Johnson. . .U.S. sales rose 11% with growth in pharmaceuticals and medical devices. . .new drugs performed well. . .in particular, the biologic Stelara, Incivo for hepatitis C, the cancer drug Zytiga, and the anticoagulant Xarelto achieved strong sales growth. . .we view the company's diverse business mix positively. Strong finances allow for share repurchases, opportunistic acquisitions and dividend growth."
"Johnson & Johnson has received a major boost as its blockbuster potential type 2 diabetes drug, Invokana (commonly known as canagliflozin), was granted U.S. Food and Drug Administration approval. The approval marks the company's first entry into the huge diabetes market. . .we currently expect the drug to achieve over $1B in peak sales."
"Johnson & Johnson's blockbuster potential experimental drug, canagliflozin, is expected to receive U.S. Food and Drug Administration approval by the end of the month. . .while the potential of the drug is much higher, currently we expect the drug to achieve over $1B in expected peak sales."
Larry Biegelsen, Wells Fargo Securities
"Johnson & Johnson finished 2012 on a strong note in terms of its pharma pipeline. . .pending pharmaceutical pipeline events in H1/13 include canagliflozin for diabetes PDUFA date around end of March, PDUFA date for Xarelto for acute coronary syndrome indication is around March 7, U.S. and European simeprevir for Hepatitus C regulatory filings in H1/13. . .we believe the company's business is starting to turn the corner and we expect the pipeline to deliver accelerating growth."
Rajeev Jashnani, UBS Securities
"Johnson & Johnson has two key opportunities on the horizon with canagliflozin and Xarelto acute coronary syndrome. . .the Street is probably baking in <$500M whereas the upside case could add $2.5B in revenues (adding ~1% to our 2013–2016 revenue compound annual growth rate of ~4%) and 6% to earnings per share by 2016."
Johnson & Johnson Content
* This is a registered trademark of Johnson & Johnson. Johnson & Johnson is not affiliated with Streetwise Reports.
Back to Top